Clinical trials: Parkinson
Parkinson Disease
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging.
- Trial name
- NCT03858270
- Testing
- Memantine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson
Impact of Exercise on Muscle Metabolism and Function for Persons With Parkinsons
This investigation assesses the impact of a strengthening program on muscle metabolism in the gastrocnemius muscle (GM) and is an essential step in the establishment of future clinical intervention for the GM in people with…
- Trial name
- NCT07720713
- Testing
- Home Exercise Program
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Vascular Parkinsonism, Parkinson's Disease
Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease
Vascular parkinsonism (VP) is defined as the presence of parkinsonian syndrome, evidence of cerebrovascular disease by brain imaging and an established relationship between the two disorders.
- Trial name
- NCT04308135
- Testing
- Neuro-radiological tools:, cognitive tests, lab investigations
- Where
- Egypt
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Alzheimer Disease, Parkinson Disease
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are: Overcome the bottleneck of early accurate diagnosis and treatment in major…
- Conditions
- Alzheimer Disease, Parkinson Disease, Epilepsy, Malignant Brain Tumor
- Trial name
- CAMIND (NCT06092125)
- Testing
- PET/MR
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Lewy Body Disease, Lewy Body Dementia
Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
- Conditions
- Lewy Body Disease, Lewy Body Dementia, Parkinson Disease, Parkinson Disease Dementia
- Trial name
- NCT07849413
- Testing
- Behavioral Tasks, MRI/MEG Scans
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson's Disease
Therapeutic Yoga to Improve Function in Parkinson's Disease
This is a single blind, randomized, wait-list controlled, phase II exploratory pilot study.
- Trial name
- NCT02902510
- Testing
- Therapeutic yoga for people with Parkinson's Disease
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Clemson University
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
How Does STN-DBS Influence Emotional Conflict Decision in Parkinson's Disease: a EEG Study
A large body of evidence points to impairment in the decoding of emotional stimuli in Parkinson's disease (PD). These changes seem to be related to dysfunction of the mesocorticolimbic projections leading to dysfunction of the…
- Trial name
- DBS-EMOTION (NCT02786680)
- Testing
- stroop test in condition DBS off, stroop test in condition DBS on
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Parkinson Disease
Effects of Neuromodulation on Brain Electric Activity of Parkinson's Disease Patients
Parkinson's disease (PD) is a neurodegenerative and progressive movement disorder, whose population incidence is increasing. It is characterized by motor symptoms such as tremor, stiffness and bradykinesia, and non-motor…
- Trial name
- NCT04221659
- Testing
- Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Federal University of Paraíba
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
Parkinson's Disease (PD), Healthy Aging
Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease
This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility…
- Trial name
- NCT07567482
- Testing
- Exoskeleton
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Centre intégré de santé et de services sociaux de l'Outaouais
Parkinson's Disease
Biomarker Discovery in Parkinson's Disease
There are approximately one million Americans who live with Parkinson's disease with 50,000 new cases per year and this rate is expected to rise with an aging population.
- Trial name
- DISCOVERY-PD (NCT02016092)
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- The Parkinson's Institute
Multisystemic Atrophy
Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) Study
Background: Multiple System Atrophy (MSA) is an atypical parkinsonian syndrome including cerebellar impairment and poor response to dopatherapy.
- Trial name
- MSAJOY (NCT01044992)
- Testing
- H215O PET, Levodopa
- Where
- 4 sites in France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Parkinson's Disease
Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease
This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.
- Trial name
- NCT03119636
- Testing
- NPC transplantation, Levodopa
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Parkinson's Disease
Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues
Parkinson's disease (PD) is associated with problems of gait such as veering, difficulty turning, an inability to perceive doorways or obstacles, and negotiate uneven terrain.
- Trial name
- NCT02610634
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Parkinson's Disease
Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of oral doses of FB-101 in healthy subjects.
- Trial name
- NCT04165837
- Testing
- FB-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.